Bismuth-Based Quadruple Rescue Therapy for H. pylori Infection

In a small, open-label trial, this regimen yielded a high H. pylori eradication rate in patients with previous treatment failure on standard triple therapy.

Standard triple therapy for Helicobacter pylori infection — omeprazole, amoxicillin, and clarithromycin (OAC) — is increasingly unsuccessful in some regions of the world because of antibiotic resistance. The European Consensus Report recommends bismuth-based quadruple therapy (BBT; bismuth subcitrate, metronidazole, and tetracycline, plus a proton-pump inhibitor) as first-line treatment in regions with high rates of clarithromycin resistance, but its effectiveness for patients with treatment failure on OAC remains unknown. In a recent manufacturer-sponsored, open-label, phase IIIb trial conducted in France, Germany, Italy, and Spain, researchers explored this issue.

Adults who had failed at least one course of OAC underwent baseline urea bre…

Reviewing Author

David J. Bjorkman, MD, MSPH (HSA), SM (Epid.)

Disclosures

Nothing to disclose

David J. Bjorkman, MD, MSPH (HSA), SM (Epid.)

Disclosures

Nothing to disclose

Bismuth-Based Quadruple Rescue Therapy for H. pylori Infection

Topics

Reviewing Author